<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01090609</url>
  </required_header>
  <id_info>
    <org_study_id>Scitech 002</org_study_id>
    <nct_id>NCT01090609</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety of Cronus® - Cobalt Chromium Coronary Stent</brief_title>
  <acronym>CRONUS</acronym>
  <official_title>Multicenter, Prospective, Non-randomized Study to Evaluate the Safety of Cronus® Cobalt Chromium Coronary Stent - Study After 9 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scitech Produtos Medicos Ltda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scitech Produtos Medicos Ltda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective this study is evaluate the performance and safety of Chronus® cobalt-chromium&#xD;
      coronary stent in patients with &quot;de novo&quot; native coronary artery lesions treated with&#xD;
      19-mm-long stents in long-term 9 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of coronary stents has optimized the results of coronary balloon angioplasty for two&#xD;
      reasons:&#xD;
&#xD;
        1. reduced acute complications, such as acute and subacute occlusion, as well as the need&#xD;
           of urgent myocardial revascularization;&#xD;
&#xD;
        2. reduced coronary restenosis. STRESS and BENESTENT 1 pivotal clinical trials7,9 laid the&#xD;
           foundations for approval and confirmation of the efficacy of coronary stents. These&#xD;
           studies showed a reduction in the binary angiographic restenosis rates from 42.1% to&#xD;
           31.6% (p&lt;0.05) and from 32% to 22% (p=0.02), respectively. The efficacy of coronary&#xD;
           stents is due to the fact that these devices reduce the acute elastic recoil and late&#xD;
           negative remodeling of coronary arteries because of their capacity to maintain the&#xD;
           vessel adequately open without reducing vessel diameter.&#xD;
&#xD;
      Cronus® stent is fabricated in cobalt-chromium. This alloy is currently used cardiovascular&#xD;
      stents and permanent implants in orthopedic (hips, knees), dental and maxillofacial&#xD;
      surgeries. Guidant and Medtronic have conducted clinical evaluations of stents fabricated&#xD;
      with a similar cobalt-chromium alloy and demonstrated safety and efficacy of the&#xD;
      investigational devices. Both stents are currently available in the European market.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Follow-up</measure>
    <time_frame>30 days after the procedure</time_frame>
    <description>All patients are invited to return for a clinical visit at 30 days post-procedure to evaluate possible adverse events and on the continuity of cardiac medication.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">263</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Stent implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cronus Stent implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stent implantation</intervention_name>
    <description>Stent implantation</description>
    <arm_group_label>Stent implantation</arm_group_label>
    <other_name>Angioplasty</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years and ≤75 years;&#xD;
&#xD;
          2. Symptomatic cardiac ischemic disease and/or documented evidence of myocardial&#xD;
             ischemia;&#xD;
&#xD;
          3. Types B1 and B2 coronary lesions (according to the ACC/AHA classification modified by&#xD;
             Ellis);&#xD;
&#xD;
          4. Target lesion located in a native coronary artery;&#xD;
&#xD;
          5. Target lesion in vessel with diameter ranging from 2.5 to 3.5 mm (by visual estimate)&#xD;
             amenable to treatment (coverage) with a 19-mm-long stent;&#xD;
&#xD;
          6. Target lesion with &gt;50% diameter stenosis (by visual estimate);&#xD;
&#xD;
          7. Acceptable candidate to myocardial revascularization surgery (coronary artery bypass&#xD;
             graft surgery);&#xD;
&#xD;
          8. The subject has been fully informed of the nature of the study, is willing to comply&#xD;
             with all study requirements and will provide written informed consent as approved by&#xD;
             the Ethics Committee of the respective clinical site.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female patients of childbearing potential;&#xD;
&#xD;
          2. Recent Q-wave myocardial infarction occurred within 48 hours prior to the index&#xD;
             procedure. Recent Q-wave or non-Q-wave myocardial infarction with still elevated&#xD;
             levels of cardiac markers;&#xD;
&#xD;
          3. Documented left ventricular ejection fraction &lt;30%;&#xD;
&#xD;
          4. Renal dysfunction (creatinine &gt; 2.0 mg/dL or 177 µmol/L);&#xD;
&#xD;
          5. Platelet count &lt;100,000 cells/mm³ or &gt;700,000 cells/mm³.;&#xD;
&#xD;
          6. White blood cell count &lt;3,000 cells/mm3;&#xD;
&#xD;
          7. Suspected or documented hepatic disease (including laboratorial evidence of&#xD;
             hepatitis);&#xD;
&#xD;
          8. Heart transplant receptor;&#xD;
&#xD;
          9. Known hypersensitivity to cobalt-chromium or to medications such as aspirin,&#xD;
             clopidogrel bisulfate (Plavix or ISCOVER), ticlopidine (Ticlid) or heparin.&#xD;
&#xD;
         10. Concurrent medical condition with a life expectancy of less than 12 months;&#xD;
&#xD;
         11. Any major medical condition that, in the Investigator's opinion, may interfere with&#xD;
             the optimal participation of the patient in this study;&#xD;
&#xD;
         12. Subject is currently participating in an investigational drug or another device study,&#xD;
             including planned participation in an investigational drug or another device study&#xD;
             during the course of the present investigation;&#xD;
&#xD;
         13. Coronary angioplasty (with or without stenting) less than 9 months before the index&#xD;
             procedure at any site of the target vessel;&#xD;
&#xD;
         14. Previous coronary angioplasty (with or without stenting) at any time (&gt;9 months) in a&#xD;
             vessel segment less than 5 mm proximal or distal to the target lesion.&#xD;
&#xD;
         15. Planned coronary angioplasty (with or without stenting) in the first 12 months after&#xD;
             the index procedure in any segment of the target vessel;&#xD;
&#xD;
        Angiography Exclusion Criteria:&#xD;
&#xD;
          1. Restenotic target lesion;&#xD;
&#xD;
          2. More than one lesion requiring treatment in the same vessel;&#xD;
&#xD;
          3. Target vessel diameter &lt;2.5 mm or &gt;3.5 mm (by visual estimation);&#xD;
&#xD;
          4. Long target lesion not amenable to treatment (coverage) with a 19-mm-long stent;&#xD;
&#xD;
          5. Unprotected coronary artery branch lesion (≥50% diameter stenosis)&#xD;
&#xD;
          6. Target lesion is located in a surgical bypass graft;&#xD;
&#xD;
          7. Total vessel occlusion (TIMI flow grade 0-1);&#xD;
&#xD;
          8. Target lesion with ostial location;&#xD;
&#xD;
          9. Target lesion located in a lateral branch bifurcation &gt;2.5mm or requiring lateral&#xD;
             branch stenting;&#xD;
&#xD;
         10. Calcified target lesion that anticipates unsuccessful/impracticable predilation;&#xD;
&#xD;
         11. Target vessel with excessive tortuosity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fausto Feres, Medicine</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Dante Pazzanese de Cardiologia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital São Salvador Goiânia</name>
      <address>
        <city>Goiânia</city>
        <state>GO</state>
        <zip>74110-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Genoveva</name>
      <address>
        <city>Goiânia</city>
        <state>GO</state>
        <zip>74670-430</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irmandade Santa Casa de Misericórdia de Belo Horizonte</name>
      <address>
        <city>Belo Horizonte</city>
        <state>MG</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Isabel</name>
      <address>
        <city>Blumenau</city>
        <state>SC</state>
        <zip>89010-906</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Dante Pazzanese de Cardiologia</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>04012-909</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Assistência Médica ao Servidor Público Estadual - Iamspe</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>04029-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da USP</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital São Paulo - UNIFESP</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>São Bernardo Apart Hospital</name>
      <address>
        <city>Colatina - ES</city>
        <zip>29700-790</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Casa de Franca</name>
      <address>
        <city>Franca - SP</city>
        <zip>14400-730</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vera Cruz</name>
      <address>
        <city>Patos de Minas - MG</city>
        <zip>38700-160</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Medicina Integral Professor Fernando Figueira - IMIP</name>
      <address>
        <city>Recife - PE</city>
        <zip>50070-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Casa de Misericórdia de São José do Rio Preto</name>
      <address>
        <city>São José do Rio Preto - SP</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.scitechmed.com</url>
    <description>Sponsor site</description>
  </link>
  <link>
    <url>http://portal2.saude.gov.br/sisnep</url>
    <description>National Information System on Ethics in Research involving Human</description>
  </link>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>March 18, 2010</study_first_submitted>
  <study_first_submitted_qc>March 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2010</study_first_posted>
  <last_update_submitted>November 13, 2014</last_update_submitted>
  <last_update_submitted_qc>November 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Stent</keyword>
  <keyword>Cobalt-Chromium coronary stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

